Clinical assessment of glimepiride (Amaril®) in the treatment of type 2 diabetes mellitus patients (results of a multicenter study)

Endokrinologya

Volumn 7, Issue 1, 2002, Pages 30-35

  Hristov, V ^a   Sheinkova, G ^a   Simeonov, S ^a   Botushanov, N ^a   Valkov, Y ^a   Tzinlikov, I ^a  

^a UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

Author keywords

Diabets; Glimepiride; Glycemic control

Indexed keywords

AMARIL; ANTIDIABETIC AGENT; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; LIPID; LONG ACTING DRUG;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FEMALE; HUMAN; HYPOGLYCEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RECORDING; WEIGHT REDUCTION;

EID: 0036300393     PISSN: 13108131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Longterm treatment of type 2 diabetes mellitus with Glimepiride is weight neutral: A Meta analysis
2. Clinical profile of Glimepiride
3. The study group on Glimepiride of the Andean countries. Clinical Prospective Latino-American experience with Glimepiride in the treatment of diabetes mellitus 2
4. Glimepiride (Amaryl) - Results of a non-interventional study in Germany
5. The evaluation of the efficacy, safety and tolerability of Glimepiride in patients with type 2 diabetes
6. Glimepiride. A review of its use in the management of type 2 diabetes mellitus
7. Differential interaction of Glimepiride and Glibenclamide with beta-cell sulfonylurea receptor. Binding characteristics
8. Glimepiride, a new, once daily sulfonilurea. A double-blind placebo-controlled study of NIDDM patients